IP Library Granted Patent US 9,439,925
Granted Patent B2
US 9,439,925 · App. 13/639,560 · Granted Sep 13, 2016

Methods and compositions for treating wounds utilizing chitosan compounds

Inventors: Shenda Baker (Upland, CA); William P. Wiesmann (Washington, DC); Ruth Baxter (Los Angeles, CA)
Assignee: SYNEDGEN, INC.
A61K31/722A61K47/4823A61L26/0023A61L26/0066A61L2300/404A61L2300/41A61L2300/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,925
App. No.
13/639,560
Granted
Sep 13, 2016
Kind
B2
Abstract

Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.

Claims (15)

1. A method of treating mucositis or ulceration in the gastrointestinal (GI) tract, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):

wherein:

n is an integer between 20 and 6000; and

each R 1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):

wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and 4-30% of R 1 substituents are a group of formula (II),

thereby treating mucositis or ulceration.

2. The method of claim 1 , wherein the composition reduces the healing time or increases the healing rate of the mucositis or ulceration.

3. The method of claim 1 , wherein the mucositis or ulceration is associated with inflammation and the composition decreases the inflammation upon administration.

4. The method of claim 1 , wherein the composition is administered topically or orally.

5. The method of claim 1 , wherein the molecular weight of the functionalized chitosan is between 5,000 and 1,000,000 Da.

6. The method of claim 1 , wherein the subject has been exposed to radiation or chemotherapy.

7. The method of claim 1 , wherein the mucositis or ulceration is the result of a wound.

8. The method of claim 7 , wherein the wound is infected.

9. The method of claim 7 , wherein the wound is a result of an acute or chronic infection.

10. The method of claim 1 , wherein the mucositis or ulceration occurs in the mouth, tongue, throat, esophagus, stomach, large intestine, small intestine, colon, or rectum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2012
From: BAKER, SHENDA M.; WIESMANN, WILLIAM P.; BAXTER, RUTH
To: SYNEDGEN, INC.
Reel/Frame 029203/0642 →
Continuity (3)
Provisional Application 61321437 · Apr 6, 2010
Provisional Application 61451430 · Mar 10, 2011
Related Publication 20130210761A1 · Aug 15, 2013